Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma

As sorafenib is a first-line drug for treating advanced hepatocellular carcinoma, sorafenib resistance has historically attracted attention. However, most of this attention has been focused on a series of mechanisms related to drug resistance arising after sorafenib treatment. In this study, we used...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ruiqi, Weng, Shuang, Xu, Jianping, Li, Zhuo, Wang, Yaru, Aizimuaji, Zulihumaer, Ma, Sheng, Zheng, Linlin, Li, Haiyang, Ying, Wantao, Rong, Weiqi, Xiao, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372478/
https://www.ncbi.nlm.nih.gov/pubmed/37520282
http://dx.doi.org/10.1016/j.csbj.2023.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372478/
https://www.ncbi.nlm.nih.gov/pubmed/37520282
http://dx.doi.org/10.1016/j.csbj.2023.07.005

Ejemplares similares